T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.